Pulmatrix Promotes Robert Clarke, PhD, to Chief Scientific Officer and Vice President of Research and Development

Leadership Role Central as Company Accelerates and Advances Novel Drug Pipeline

LEXINGTON, Mass.--(BUSINESS WIRE)-- Pulmatrix, a clinical stage biotechnology company discovering and developing a new class of therapies for the prevention, treatment and control of respiratory diseases, announced today that it was promoting Robert Clarke, PhD, to the role of Chief Scientific Officer (CSO) and Vice President of Research and Development effective immediately. Dr. Clarke has been overseeing the company’s research efforts and has been pivotal in the development of Pulmatrix’s inhaled therapeutic technologies since joining the company in 2004, shortly after the company was founded in 2003. He will continue to report to Robert Connelly, President and CEO of Pulmatrix.

“We are delighted to promote Bob to the role of CSO and Vice President of Research and Development at this pivotal time, when Pulmatrix is poised to make substantial progress in accelerating and expanding our pipeline of novel inhaled drug candidates," said Robert Connelly, President and CEO of Pulmatrix. "Bob has been pivotal in the development of our core technologies. In particular, his expertise in respiratory biology and drug delivery are the right combination we need to push our breakthrough technologies forward. We will continue to rely on both his deep scientific insights and strong leadership as we rapidly move through our next stage of growth.”

“I am very enthusiastic about taking on this expanded role at Pulmatrix,” added Robert Clarke, PhD, CSO and Vice President of Research and Development. “It is an honor to lead our capable team of researchers at such an important time in our company’s evolution. Advancing from our novel multi-factorial therapeutic strategy and growing pipeline of drug candidates, Pulmatrix is well positioned to deliver a number of products with the potential to make a transformational difference to patients in need in several chronic diseases, including COPD and CF.”

Dr. Clarke joined Pulmatrix from Alkermes in 2004, leading the research efforts dedicated to understanding the impact of Pulmatrix technologies in respiratory disease, most recently as Pulmatrix’s Vice President of Research. Dr. Clarke previously worked on research and development of Alkermes’ portfolio of drug delivery technologies initially focused on the AIR inhaled particle technology. Dr. Clarke holds a degree in Biomedical Engineering from Boston University, and a PhD in Physiology from Johns Hopkins University. Following his studies, he completed post-doctoral training in Pathology and Respiratory Biology at Brigham and Women’s Hospital and Harvard University. Dr. Clarke has co-authored over 90 chapters, papers, and abstracts focused on pulmonary drug delivery and the role of particles and infection in the lung.

About Pulmatrix

Pulmatrix is a clinical stage biotechnology company discovering and developing a new class of therapies for the prevention, treatment and control of respiratory diseases. Pulmatrix’s lead proprietary therapies, called inhaled cationic airway lining modulators (iCALM), are a novel approach to prevent and treat acute exacerbations and improve lung function in patients with chronic respiratory diseases. iCALM therapies have broad potential to treat and prevent a wide range of respiratory diseases, including respiratory infections such as influenza; ventilator associated pneumonia (VAP) and respiratory syncytial virus (RSV), as well as progressive or chronic respiratory diseases such as COPD, asthma, and cystic fibrosis. For additional information about the Company, please visit http://www.pulmatrix.com.



CONTACT:

The Yates Network
Kathryn Morris, 845-635-9828
[email protected]

KEYWORDS:   United States  North America  Massachusetts

INDUSTRY KEYWORDS:   Health  Biotechnology  Pharmaceutical

MEDIA:

Logo
 Logo

Suggested Articles

Zentalis is coming out of stealth with an $85 million series C, which will propel its lead programs into pivotal trials and broaden its pipeline.

The planned takeover centers on ARQ 531, a BTK inhibitor that triggered durable responses in patients with B-cell malignancies.

At ASH, Dana-Farber researchers presented promising preclinical data on AMG 701, Amgen's long-lasting BiTE for multiple myeloma, but rivals loom.